Fighting Alzheimer’s with Movement: The Role of Physical Activity in Disease Management
DOI:
https://doi.org/10.12775/QS.2025.38.58214Keywords
Alzheimer's disease, Alzheimer's disease and physical activity, dementia, cognitive function, disease progression, exerciseAbstract
Introduction and purpose
This article investigates the role of physical activity in Alzheimer's disease. It reviews existing research to explore how exercise affects cognitive decline, identifies mechanisms through which physical activity may slow disease progression, and evaluates practical recommendations for integrating exercise into Alzheimer's management. The goal is to provide valuable insights for individuals and healthcare professionals on using physical activity as a non-pharmacological approach to managing Alzheimer's disease.
State of knowledge
The article examines the current literature on Alzheimer's disease, with a focus on the effects of physical activity on cognitive function. By understanding the relationship between exercise and brain health, targeted interventions can be developed to slow cognitive decline. The impact of physical activity on overall Alzheimer's disease progression is also highlighted.
Material and Methods
A review of literature from 2009 to 2024 was conducted using databases such as PubMed, ScienceDirect, and Google Scholar. Keywords included "Alzheimer's disease," "physical activity," "cognitive decline," and "exercise." The review focused on English-language primary research articles from peer-reviewed journals.
Summary
The review underscores the positive effects of physical activity in managing Alzheimer's disease. Evidence suggests that regular exercise helps improve cognitive function, slow disease progression, and enhance overall quality of life. This highlights the effectiveness of physical activity as a valuable, non-pharmacological approach to managing Alzheimer's.
References
[1]
Jiang T, Yu JT, Tian Y, Tan L. Epidemiology and etiology of Alzheimer's disease: from genetic to non-genetic factors. Curr Alzheimer Res. 2013;10(8):852-867. doi:10.2174/15672050113109990155
[2]
Lynch C. World Alzheimer Report 2019: Attitudes to dementia, a global survey: Public health: Engaging people in ADRD research. Alzheimer’s & Dementia. 2020;16(S10):e038255. doi:10.1002/alz.038255
[3]
Henderson AS. The epidemiology of Alzheimer's disease. Br Med Bull. 1986;42(1):3-10. doi:10.1093/oxfordjournals.bmb.a072095
[4]
Jahn H. Memory loss in Alzheimer's disease. Dialogues Clin Neurosci. 2013;15(4):445-454. doi:10.31887/DCNS.2013.15.4/hjahn
[5]
Huntley JD, Howard RJ. Working memory in early Alzheimer's disease: a neuropsychological review. Int J Geriatr Psychiatry. 2010;25(2):121-132. doi:10.1002/gps.2314
[6]
Barnes J, Dickerson BC, Frost C, Jiskoot LC, Wolk D, van der Flier WM. Alzheimer's disease first symptoms are age dependent: Evidence from the NACC dataset. Alzheimers Dement. 2015;11(11):1349-1357. doi:10.1016/j.jalz.2014.12.007
[7]
Nadkarni NK, Levy-Cooperman N, Black SE. Functional correlates of instrumental activities of daily living in mild Alzheimer's disease. Neurobiol Aging. 2012;33(1):53-60. doi:10.1016/j.neurobiolaging.2010.02.001
[8]
Klimova B, Maresova P, Valis M, Hort J, Kuca K. Alzheimer's disease and language impairments: social intervention and medical treatment. Clin Interv Aging. 2015;10:1401-1407. Published 2015 Aug 27. doi:10.2147/CIA.S89714
[9]
Phillips LH, Scott C, Henry JD, Mowat D, Bell JS. Emotion perception in Alzheimer's disease and mood disorder in old age. Psychol Aging. 2010;25(1):38-47. doi:10.1037/a0017369
[10]
Robins Wahlin TB, Byrne GJ. Personality changes in Alzheimer's disease: a systematic review. Int J Geriatr Psychiatry. 2011;26(10):1019-1029. doi:10.1002/gps.2655
[11]
Affoo RH, Foley N, Rosenbek J, Kevin Shoemaker J, Martin RE. Swallowing dysfunction and autonomic nervous system dysfunction in Alzheimer's disease: a scoping review of the evidence. J Am Geriatr Soc. 2013;61(12):2203-2213. doi:10.1111/jgs.12553
[12]
Isik AT. Late onset Alzheimer's disease in older people. Clin Interv Aging. 2010;5:307-311. Published 2010 Oct 11. doi:10.2147/CIA.S11718
[13]
2021 Alzheimer's disease facts and figures. Alzheimers Dement. 2021;17(3):327-406. doi:10.1002/alz.12328
[14]
Emrani S, Arain HA, DeMarshall C, Nuriel T. APOE4 is associated with cognitive and pathological heterogeneity in patients with Alzheimer's disease: a systematic review. Alzheimers Res Ther. 2020;12(1):141. Published 2020 Nov 4. doi:10.1186/s13195-020-00712-4
[15]
A Armstrong R. Risk factors for Alzheimer's disease. Folia Neuropathol. 2019;57(2):87-105. doi:10.5114/fn.2019.85929
[16]
Anderson LN, McCaul KD, Langley LK. Common-sense beliefs about the prevention of Alzheimer's disease. Aging Ment Health. 2011;15(7):922-931. doi:10.1080/13607863.2011.569478
[17]
Marcello E, Gardoni F, Di Luca M. Alzheimer's disease and modern lifestyle: what is the role of stress?. J Neurochem. 2015;134(5):795-798. doi:10.1111/jnc.13210
[18]
A. Armstrong R. Review articleWhat causes alzheimer’s disease?. Folia Neuropathologica. 2013;51(3):169-188. doi:10.5114/fn.2013.37702.
[19]
Ashrafian H, Zadeh EH, Khan RH. Review on Alzheimer's disease: Inhibition of amyloid beta and tau tangle formation. Int J Biol Macromol. 2021;167:382-394. doi:10.1016/j.ijbiomac.2020.11.192
[20]
Murphy MP, LeVine H 3rd. Alzheimer's disease and the amyloid-beta peptide. J Alzheimers Dis. 2010;19(1):311-323. doi:10.3233/JAD-2010-1221
[21]
Horie K, Barthélemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau tangle and clinical stages of Alzheimer's disease [published correction appears in Brain. 2021 Oct 22;144(9):e82. doi: 10.1093/brain/awab227]. Brain. 2021;144(2):515-527. doi:10.1093/brain/awaa373
[22]
Busche MA, Hyman BT. Synergy between amyloid-β and tau in Alzheimer's disease. Nat Neurosci. 2020;23(10):1183-1193. doi:10.1038/s41593-020-0687-6
[23]
Martorana A, Esposito Z, Koch G. Beyond the cholinergic hypothesis: do current drugs work in Alzheimer's disease?. CNS Neurosci Ther. 2010;16(4):235-245. doi:10.1111/j.1755-5949.2010.00175.x
[24]
Trejo-Lopez JA, Yachnis AT, Prokop S. Neuropathology of Alzheimer's Disease. Neurotherapeutics. 2022;19(1):173-185. doi:10.1007/s13311-021-01146-y
[25]
Dickstein DL, Walsh J, Brautigam H, Stockton SD Jr, Gandy S, Hof PR. Role of vascular risk factors and vascular dysfunction in Alzheimer's disease. Mt Sinai J Med. 2010;77(1):82-102. doi:10.1002/msj.20155
[26]
Dos Santos Picanco LC, Ozela PF, de Fatima de Brito Brito M, et al. Alzheimer's Disease: A Review from the Pathophysiology to Diagnosis, New Perspectives for Pharmacological Treatment. Curr Med Chem. 2018;25(26):3141-3159. doi:10.2174/0929867323666161213101126
[27]
Atri A. The Alzheimer's Disease Clinical Spectrum: Diagnosis and Management. Med Clin North Am. 2019;103(2):263-293. doi:10.1016/j.mcna.2018.10.009
[28]
Hort J, O'Brien JT, Gainotti G, et al. EFNS guidelines for the diagnosis and management of Alzheimer's disease. Eur J Neurol. 2010;17(10):1236-1248. doi:10.1111/j.1468-1331.2010.03040.x
[29]
Laske C, Sohrabi HR, Frost SM, et al. Innovative diagnostic tools for early detection of Alzheimer's disease. Alzheimers Dement. 2015;11(5):561-578. doi:10.1016/j.jalz.2014.06.004
[30]
Sengoku R. Aging and Alzheimer's disease pathology. Neuropathology. 2020;40(1):22-29. doi:10.1111/neup.12626
[31]
Vemuri P, Jack CR Jr. Role of structural MRI in Alzheimer's disease. Alzheimers Res Ther. 2010;2(4):23. Published 2010 Aug 31. doi:10.1186/alzrt47
[32]
Marcus C, Mena E, Subramaniam RM. Brain PET in the diagnosis of Alzheimer's disease. Clin Nucl Med. 2014;39(10):e413-e426. doi:10.1097/RLU.0000000000000547
[33]
Blennow K. A Review of Fluid Biomarkers for Alzheimer's Disease: Moving from CSF to Blood. Neurol Ther. 2017;6(Suppl 1):15-24. doi:10.1007/s40120-017-0073-9
[34]
Rasmussen J, Langerman H. Alzheimer's Disease - Why We Need Early Diagnosis. Degener Neurol Neuromuscul Dis. 2019;9:123-130. Published 2019 Dec 24. doi:10.2147/DNND.S228939 [35]
Vaz M, Silvestre S. Alzheimer's disease: Recent treatment strategies. Eur J Pharmacol. 2020;887:173554. doi:10.1016/j.ejphar.2020.173554
[36]
Massoud F, Gauthier S. Update on the pharmacological treatment of Alzheimer's disease. Curr Neuropharmacol. 2010;8(1):69-80. doi:10.2174/157015910790909520
[37]
Kishi T, Matsunaga S, Oya K, Nomura I, Ikuta T, Iwata N. Memantine for Alzheimer's Disease: An Updated Systematic Review and Meta-analysis. J Alzheimers Dis. 2017;60(2):401-425. doi:10.3233/JAD-170424 [38]
Vaz M, Silva V, Monteiro C, Silvestre S. Role of Aducanumab in the Treatment of Alzheimer's Disease: Challenges and Opportunities. Clin Interv Aging. 2022;17:797-810. Published 2022 May 18. doi:10.2147/CIA.S325026 [39]
Ko Y, Chye SM. Lifestyle intervention to prevent Alzheimer's disease. Rev Neurosci. Published online August 17, 2020. doi:10.1515/revneuro-2020-0072
[40]
Mendiola-Precoma J, Berumen LC, Padilla K, Garcia-Alcocer G. Therapies for Prevention and Treatment of Alzheimer's Disease. Biomed Res Int. 2016;2016:2589276. doi:10.1155/2016/2589276 [41]
Shah RS, Lee HG, Xiongwei Z, Perry G, Smith MA, Castellani RJ. Current approaches in the treatment of Alzheimer's disease. Biomed Pharmacother. 2008;62(4):199-207. doi:10.1016/j.biopha.2008.02.005 [42]
Vos SJ, Verhey F, Frölich L, et al. Prevalence and prognosis of Alzheimer's disease at the mild cognitive impairment stage. Brain. 2015;138(Pt 5):1327-1338. doi:10.1093/brain/awv029
[43]
Varma VR, Watts A. Daily Physical Activity Patterns During the Early Stage of Alzheimer's Disease. J Alzheimers Dis. 2017;55(2):659-667. doi:10.3233/JAD-160582
[44]
Reitz C. Genetic diagnosis and prognosis of Alzheimer's disease: challenges and opportunities. Expert Rev Mol Diagn. 2015;15(3):339-348. doi:10.1586/14737159.2015.1002469
[45]
Stephen R, Hongisto K, Solomon A, Lönnroos E. Physical Activity and Alzheimer's Disease: A Systematic Review. J Gerontol A Biol Sci Med Sci. 2017;72(6):733-739. doi:10.1093/gerona/glw251
[46]
Rosendorff C, Beeri MS, Silverman JM. Cardiovascular risk factors for Alzheimer's disease. Am J Geriatr Cardiol. 2007;16(3):143-149. doi:10.1111/j.1076-7460.2007.06696.x
[47]
Leszek J, Mikhaylenko EV, Belousov DM, et al. The Links between Cardiovascular Diseases and Alzheimer's Disease. Curr Neuropharmacol. 2021;19(2):152-169. doi:10.2174/1570159X18666200729093724 [48]
Erickson KI, Weinstein AM, Lopez OL. Physical activity, brain plasticity, and Alzheimer's disease. Arch Med Res. 2012;43(8):615-621. doi:10.1016/j.arcmed.2012.09.008
[49]
Coelho FG, Vital TM, Stein AM, et al. Acute aerobic exercise increases brain-derived neurotrophic factor levels in elderly with Alzheimer's disease. J Alzheimers Dis. 2014;39(2):401-408. doi:10.3233/JAD-131073
[50]
Stranahan AM, Martin B, Maudsley S. Anti-inflammatory effects of physical activity in relationship to improved cognitive status in humans and mouse models of Alzheimer's disease. Curr Alzheimer Res. 2012;9(1):86-92. doi:10.2174/156720512799015019 [51]
Ribarič S. Physical Exercise, a Potential Non-Pharmacological Intervention for Attenuating Neuroinflammation and Cognitive Decline in Alzheimer's Disease Patients. Int J Mol Sci. 2022;23(6):3245. Published 2022 Mar 17. doi:10.3390/ijms23063245 [52]
Lautenschlager NT, Cox K, Kurz AF. Physical activity and mild cognitive impairment and Alzheimer's disease. Curr Neurol Neurosci Rep. 2010;10(5):352-358. doi:10.1007/s11910-010-0121-7 [53]
Kępka A, Ochocińska A, Borzym-Kluczyk M, et al. Healthy Food Pyramid as Well as Physical and Mental Activity in the Prevention of Alzheimer's Disease. Nutrients. 2022;14(8):1534. Published 2022 Apr 7. doi:10.3390/nu14081534 [54]
Sobol NA, Hoffmann K, Frederiksen KS, et al. Effect of aerobic exercise on physical performance in patients with Alzheimer's disease. Alzheimers Dement. 2016;12(12):1207-1215. doi:10.1016/j.jalz.2016.05.004 [55]
Chen WW, Zhang X, Huang WJ. Role of physical exercise in Alzheimer's disease. Biomed Rep. 2016;4(4):403-407. doi:10.3892/br.2016.607
[56]
De la Rosa A, Olaso-Gonzalez G, Arc-Chagnaud C, et al. Physical exercise in the prevention and treatment of Alzheimer's disease. J Sport Health Sci. 2020;9(5):394-404. doi:10.1016/j.jshs.2020.01.004
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Agnieszka Kosińska, Magdalena Balwierz, Karolina Kalinowska, Urszula Świrk, Jan Karczmarz, Joanna Orzechowska, Marika Gutowska, Michał Orzechowski, Aleksandra Paprocka, Paulina Fijałek

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Stats
Number of views and downloads: 39
Number of citations: 0